ANOTHER PATENT EXPLODING COMPANY
ARENA is not a one trick pony this was issued today
United States Patent Application 20130184307
Kind Code A1
Jones; Robert M. ; et al. July 18, 2013
SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS
The present invention relates to certain substituted tricyclic acid derivatives of Formula (I) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. ##STR00001## Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1-associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, myocardial ischemia-reperfusion injury, hypertensive nephropathy, glomerulosclerosis, gastritis, polymyositis, thyroiditis, vitiligo, hepatitis, biliary cirrhosis, microbial infections and associated diseases, viral infections and associated diseases, diseases and disorders mediated by lymphocytes, auto immune diseases, inflammatory diseases, and cancer.
Inventors: Jones; Robert M.; (San Diego, CA) ; Buzard; Daniel J.; (San Diego, CA) ; Kawasaki; Andrew M.; (San Diego, CA) ; Kim; Sun Hee; (San Diego, CA) ; Thoresen; Lars; (Venice, CA) ; Lehmann; Juerg; (San Diego, CA) ; Zhu; Xiuwen; (San Diego, CA)
Arena Pharmaceuticals, Inc.;
Arena Pharmaceuticals, Inc.